Dr. Jahanzeb on Overcoming HER2 Resistance in Breast Cancer

Mohammad Jahanzeb, MD
Published: Tuesday, Aug 04, 2015



Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami’s Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.

The addition of pertuzumab for the treatment of HER2-positive breast cancer is a mechanism that has been implemented to help overcome resistance, Jahanzeb explains. Moreover, everolimus, small molecular TKIs such as lapatinib, or antibody drug conjugates such as T-DM1, would also work intracellularly.

Jahanzeb explains that additional agents, such as HER2-TDB, which targets HER2 and conditionally activates T cells, vaccines, CDK4/6 and cell cycle pathway inhibitors, and immunotherapy agents such as pembrolizumab or nivolumab are all approaches to take in this space.



Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology Oncology, University of Miami’s Miller School of Medicine, discusses potential mechanisms for overcoming HER2 resistance in breast cancer.

The addition of pertuzumab for the treatment of HER2-positive breast cancer is a mechanism that has been implemented to help overcome resistance, Jahanzeb explains. Moreover, everolimus, small molecular TKIs such as lapatinib, or antibody drug conjugates such as T-DM1, would also work intracellularly.

Jahanzeb explains that additional agents, such as HER2-TDB, which targets HER2 and conditionally activates T cells, vaccines, CDK4/6 and cell cycle pathway inhibitors, and immunotherapy agents such as pembrolizumab or nivolumab are all approaches to take in this space.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x